Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. Zarnegar-Lumley S, et al. Among authors: atallah e. Blood Adv. 2023 Oct 10;7(19):5941-5953. doi: 10.1182/bloodadvances.2022008282. Blood Adv. 2023. PMID: 37267439 Free PMC article.
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Sekeres MA, et al. Among authors: atallah e. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9. J Clin Oncol. 2017. PMID: 28486043 Free PMC article. Clinical Trial.
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Atallah E, et al. BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1. BMC Cancer. 2018. PMID: 29609532 Free PMC article.
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.
Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Badar T, et al. Among authors: atallah e. Blood Adv. 2020 May 26;4(10):2308-2316. doi: 10.1182/bloodadvances.2019001381. Blood Adv. 2020. PMID: 32453836 Free PMC article.
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M. Goldberg AD, et al. Among authors: atallah e. Leuk Res. 2020 Aug;95:106385. doi: 10.1016/j.leukres.2020.106385. Epub 2020 Jun 7. Leuk Res. 2020. PMID: 32521310 Clinical Trial.
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Atallah E, et al. JAMA Oncol. 2021 Jan 1;7(1):42-50. doi: 10.1001/jamaoncol.2020.5774. JAMA Oncol. 2021. PMID: 33180106 Free PMC article. Clinical Trial.
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE. Schoenbeck KL, et al. Among authors: atallah e. J Natl Cancer Inst. 2022 Jan 11;114(1):160-164. doi: 10.1093/jnci/djab184. J Natl Cancer Inst. 2022. PMID: 34491344 Free PMC article.
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Badar T, et al. Among authors: atallah e. Am J Hematol. 2022 Jul;97(7):E232-E235. doi: 10.1002/ajh.26546. Epub 2022 Mar 30. Am J Hematol. 2022. PMID: 35338673 Free article. No abstract available.
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Flynn KE, Atallah E, Lin L, Shah NP, Silver RT, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP. Flynn KE, et al. Among authors: atallah e. Haematologica. 2022 Nov 1;107(11):2641-2649. doi: 10.3324/haematol.2021.280377. Haematologica. 2022. PMID: 35511672 Free PMC article. Clinical Trial.
184 results